October 26, 2018 – By Catherine Smith
InflaRx N.V. (NASDAQ:IFRX)’s earnings report is anticipated by WallStreet on November, 8, RTT reports. 241.67% negative EPS growth is what analysts predict. $-0.12 EPS was published for last quarter. Ticker’s shares touched $32.35 during the last trading session after 1.13% change.Currently InflaRx N.V. is after 0.00% change in last October 26, 2017. IFRX has 1,408 shares volume. IFRX underperformed by 15.62% the S&P 500.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe.The firm is worth $830.17 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases.Last it reported negative earnings. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
There’s a substantial InflaRx N.V. (NASDAQ:IFRX) news posted by Nasdaq.com. It’s an article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within Dropbox, Kura Oncology, DHT, Wayfair, US Foods …” on October 23, 2018.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.